Domain Not Resolving

Euro

nginx

Cloudflare CDN

CrUX Dataset

Cloudflare

CrUX Top 50m

Cloudflare Network Error Logging

HSTS IncludeSubdomains PreLoad

Java EE

Scientific Project Manager

Sandra Santasusagna

Information Technology Manager

Victor Rojas Cifuentes

Finance and Administration

Kim Hawkins

Chief Financial Officer

Susan Vuong

Engineering

Tianlu Li

Ramon Felciano

​SARA MARSAL

FOUNDER AND CHIEF MEDICAL OFFICER

Manuel López-Figueroa

Chief Operating Officer

Eric Perakslis

Senior Vice President & Chief Technology Officer (CTO)

Juan Harrison

Chief Executive Officer

Toni Julià

Chief Data Scientist

RICHARD M. MYERS

FOUNDER AND CHIEF SCIENTIFIC ADVISOR

Health Care Companies With Less Than $1B in Revenue (Top 10K)

Europe Biotechnology Female Founded Companies

Health Care Female Founded Companies (Top 10K)

Barcelona Companies With Fewer Than 1000 Employees

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.

Union Chimique Belge

Corporate Round - IMIDomics

Evotec

DNS Capital

Series A - IMIDomics

Barcelona

Catalonia

Spain

Europe

IMIDomics

UCB takes stake in immune-mediated disease specialist

In Brief This Week: MLA Diagnostics, BC Platforms, Oncocyte ...

Other news to note for Dec. 6, 2023

IMIDomics and Bristol Myers Squibb Expand Long-Standing Partnership to Advance Immune-Mediated Inflammatory ...

IMIDomics and Bristol Myers Squibb Expand Partnership to Revolutionize IMID Research and Development

IMIDomics Strengthens its Leadership with the Addition of Dr. Eric Perakslis to its Executive Team and Dr. Ramon Felciano to its Advisory Team

IMIDomics Announces Strategic Agreement with WuXi ...

United States

North America

Sweden

IMIDomics is dedicated to discovering and developing next-generation medicines for immune-mediated inflammatory diseases (IMIDs) by leveraging proprietary patient data and advanced computational analysis.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 6, 2024 4:12 PM	ad97ae2d
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 6, 2024 4:12 PM	6154f9fd
company summary	general
signals	general
crunchbase trigger	general	Oct 29, 2024 5:10 PM	a44f48f5
crunchbase profile	general	Oct 30, 2024 5:56 AM	a04564cd
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	0e506753
peers	general
news basic	general	Mar 6, 2024 4:12 PM	ecaec02b
bundesanzeiger	filings
financials download nd	financials
private financials	financials

IMID

COM:IMIDOMICS

IMIDomics